Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback

April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […] Read More